Literature DB >> 11726091

The central opioid system in liver disease and its complications.

C Yurdaydin1.   

Abstract

The best known example of an interaction between the liver and the brain is hepatic encephalopathy. In the 90s a central nervous system origin of the pruritus of cholestatic liver disease and more recently of fatigue of liver disease has been suggested. Hence, three important manifestations of liver disease may be of central origin. Evidence is accumulating that the central opioid system is involved in the development of these manifestations. This short review summarizes current knowledge on the role of the opioid system in development of these liver disease manifestations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726091     DOI: 10.1023/a:1011618729660

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  32 in total

1.  Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy.

Authors:  E A Jones
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

2.  Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.

Authors:  E A Jones; L R Dekker
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

3.  Relief of intractable pruritus with naloxone.

Authors:  J E Bernstein; R Swift
Journal:  Arch Dermatol       Date:  1979-11

4.  Comparison of the effects of GABA and enkephalin on synaptically evoked activity in the rat striatum.

Authors:  J P Fry; W Zieglgänsberger
Journal:  Appl Neurophysiol       Date:  1979

5.  Combination treatment of hepatic encephalopathy due to thioacetamide-induced fulminant hepatic failure in the rat with benzodiazepine and opioid receptor antagonists.

Authors:  T Celik; T Uzbay; K Cinar; H Bozkaya; O Uzunalimoglu; C Yurdaydin
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

6.  Naloxone in hepatic encephalopathy.

Authors:  S Ozsoylu; N Koçak
Journal:  Am J Dis Child       Date:  1985-08

7.  Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases.

Authors:  D Metze; S Reimann; S Beissert; T Luger
Journal:  J Am Acad Dermatol       Date:  1999-10       Impact factor: 11.527

8.  Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment.

Authors:  M G Swain; M Maric
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

9.  Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists.

Authors:  C Yurdaydin; Y Li; J H Ha; E A Jones; R Rothman; A S Basile
Journal:  J Pharmacol Exp Ther       Date:  1995-04       Impact factor: 4.030

Review 10.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

View more
  1 in total

1.  Pituitary protein 7B2 plasma levels in patients with liver disease: Comparisons with other hormones and neuropeptides.

Authors:  Maria S Venetikou; Luke Meleagros; Mohhammad A Ghatei; Stephen R Bloom
Journal:  Oncol Lett       Date:  2013-06-07       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.